Precision Oncology Market (By Product Type; By Cancer Type; By End-use: Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Precision Oncology Market 

5.1. COVID-19 Landscape: Precision Oncology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Precision Oncology Market, By Product type

8.1. Precision Oncology Market, by Product type, 2024-2033

8.1.1 Diagnostics

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Therapeutics

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Precision Oncology Market, By Cancer type

9.1. Precision Oncology Market, by Cancer type, 2024-2033

9.1.1. Breast cancer

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Colorectal cancer

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Cervical cancer

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Prostate cancer

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Lung cancer

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.5. Other cancers

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Precision Oncology Market, By End use 

10.1. Precision Oncology Market, by End use, 2024-2033

10.1.1. Hospitals & Diagnostic Laboratories

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Pharmaceutical & Biotechnology companies

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Healthcare data companies

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Precision Oncology Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product type (2021-2033)

11.1.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.1.3. Market Revenue and Forecast, by End use (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product type (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End use (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product type (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End use (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product type (2021-2033)

11.2.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.2.3. Market Revenue and Forecast, by End use (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product type (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End use (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product type (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End use (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product type (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End use (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product type (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End use (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product type (2021-2033)

11.3.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.3.3. Market Revenue and Forecast, by End use (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product type (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End use (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product type (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End use (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product type (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End use (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product type (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End use (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product type (2021-2033)

11.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.4.3. Market Revenue and Forecast, by End use (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product type (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End use (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product type (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End use (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product type (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End use (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product type (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End use (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product type (2021-2033)

11.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.5.3. Market Revenue and Forecast, by End use (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product type (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End use (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product type (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Cancer type (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End use (2021-2033)

Chapter 12. Company Profiles

12.1. F Hoffmann-La Roche AG

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Thermo Fisher Scientific Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Invitae Corporation

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Bristol-Myers Squibb

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. QIAGEN

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Illumina, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Quest Diagnostics

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Novartis AG

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. AstraZeneca

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Laboratory Corporation of America Holdings

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Frequently Asked Questions

The global precision oncology market size was reached at USD 105.71 billion in 2023 and it is projected to hit around USD 267.53 billion by 2033.

The global precision oncology market is growing at a compound annual growth rate (CAGR) of 9.73% from 2024 to 2033.

The North America region has accounted for the largest precision oncology market share in 2023.

Report Details

  • Report Code:39869
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:January 2024
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers